Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Purchases 9,004 Shares of Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par acquired 9,004 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were acquired at an average price of $26.28 per share, with a total value of $236,625.12. Following the completion of the purchase, the insider owned 6,850,237 shares of the company’s stock, valued at $180,024,228.36. This trade represents a 0.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, October 29th, Venrock Healthcare Capital Par purchased 1,000 shares of Lycia Therapeutics stock. The stock was bought at an average price of $26.33 per share, with a total value of $26,330.00.
• On Wednesday, October 28th, Venrock Healthcare Capital Par bought 15,000 shares of Lycia Therapeutics stock. The stock was bought at an average price of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $18.04 per share, for a total transaction of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par purchased 52,939 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.91 per share, with a total value of $1,371,649.49.

Lycia Therapeutics Stock Performance

LYCA stock traded down $1.33 during midday trading on Friday, hitting $26.40. 202,428 shares of the company’s stock were exchanged, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a 12-month low of $22.19 and a 12-month high of $36.49.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.